- Report
- October 2024
- 180 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Report
- April 2023
- 79 Pages
Global
From €3500EUR$3,943USD£3,046GBP
- Report
- April 2023
- 81 Pages
Global
From €3500EUR$3,943USD£3,046GBP
- Report
- March 2025
- 50 Pages
Global
From €2520EUR$2,650USD£2,119GBP
Amifostine is a drug used in the treatment of lung cancer. It is a prodrug, meaning it is converted into an active form in the body. It works by protecting healthy cells from the toxic effects of chemotherapy and radiation therapy. It is administered intravenously and is usually given prior to radiation therapy. It is also used to reduce the risk of kidney damage caused by certain chemotherapy drugs.
Amifostine is approved by the US Food and Drug Administration (FDA) for the reduction of kidney damage caused by certain chemotherapy drugs. It is also approved for the protection of healthy cells from the toxic effects of radiation therapy.
The market for Amifostine is mainly driven by the increasing prevalence of lung cancer and the growing demand for effective treatments. The increasing awareness of the drug’s benefits is also driving the market.
Some of the major companies in the Amifostine market include Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Sanofi. Show Less Read more